English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/167026
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:


Identification of a novel 2-oxindole fluorinated derivative as in vivo antitumor agent for prostate cancer acting via AMPK activation

AuthorsBort Bueno, Alicia; Quesada Sánchez, Sergio; Ramos-Torres, Ágata; Gargantilla, Marta; Priego, Eva María ; Raynal, S.; Lepifre, F.; Gasalla, J.M.; Rodriguez-Henche, Nieves; Castro, Ana ; Díaz-Laviada, Inés
Issue Date2018
PublisherNature Publishing Group
CitationScientific Reports 8 (2018)
AbstractThe key metabolic sensor adenosine monophosphate-dependent kinase (AMPK) has emerged as a promising therapeutic target for cancer prevention and treatment. Besides its role in energy homeostasis, AMPK blocks cell cycle, regulates autophagy and suppresses the anabolic processes required for rapid cell growth. AMPK is especially relevant in prostate cancer in which activation of lipogenic pathways correlate with tumor progression and aggressiveness. This study reports the discovery of a new series of 2-oxindole derivatives whose AMPK modulatory ability, as well as the antitumoral profile in prostate cancer cells, was evaluated. One of the assayed compounds, compound 8c, notably activated AMPK in cultured PC-3, DU145 and LNCaP prostate cancer cells. Likewise, compound 8c caused PC-3, DU145 and LNCaP cells viability inhibition. Selective knocking down of α1 or α2 isoforms as well as in vitro assays using human recombinant α1β1γ1 or α2β1γ1 AMPK isoforms revealed that compound 8c exhibit preference for AMPKα1. Consistent with efficacy at the cellular level, compound 8c was potent in suppressing the growth of PC-3 xenograft tumors. In conclusion, our results show that a new 2-oxindole fluorinated derivative exerts potent in vivo antitumor actions against prostate cancer cells, indicating a promising clinical therapeutic strategy for the treatment of androgen-independent prostate cancer.
Publisher version (URL)http://dx.doi.org/10.1038/s41598-018-22690-2
Identifiersdoi: 10.1038/s41598-018-22690-2
issn: 2045-2322
e-issn: 2045-2322
Appears in Collections:(IQM) Artículos
Files in This Item:
File Description SizeFormat 
Scientific reports (2018).pdf3,9 MBAdobe PDFThumbnail
Show full item record
Review this work

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.